Genomics in Drug Discovery and Development Training Workshop 2023
Speaker Biographies

Carolina Haefliger

Carolina Haefliger is a physician and clinical geneticist by training. Carolina is currently the Head of Translational Medicine at Debiopharm International, based in Lausanne, Switzerland. Having worked in the Biotech and Pharma industries for more than 19 years.

Carolina has experience of working with biomarkers, genomics, and precision medicine, as well as translational medicine in the areas of oncology, cardiovascular, metabolism, and kidney disease.

Helen Stevens

Helen is a Principal Scientist at the Centre for Genomics Research at AstraZeneca. Her role is to advise study teams, ethics committees and biobanks from AstraZeneca and major collaborations, to enable sample collection and analysis of up to two million genomes.

Driving inclusion of broad, scientific, health related pharmacogenomics within clinical trials in an ethical and compliant way. Enthusiastic about generating sustainable, usable genomics cohorts, from consent through to biobanking and associated responsible use of data. Transforming drug development through genomics. Follows the dynamic horizon of Country regulations regarding collection and use of genomic samples and derived data.

Stewart MacArthur

Stewart MacArthur is a Director if Bioinformatics at AstraZeneca. His role involves overseeing the delivery of informatics solutions for the two millions genomes project.

Richard Turner

Richard Turner is a director in Genomic Sciences and Head of Pharmacogenetics at GSK. He studied medicine at the University of Cambridge and completed clinical training in Clinical Pharmacology and Therapeutics with General Internal Medicine in Liverpool. Prior to joining GSK, he held an Academic Clinical Lectureship and a Health Education England Genomics Research Fellowship.

Jonathan Mitchell

Jonathan Mitchell joined AstraZeneca as an analyst in the Centre for Genomics Research (CGR) in 2021 from Genomics England where he worked as part of the team developing the pipeline to bring whole genome sequencing testing to cancer patients in the NHS. As an analyst at the CGR, Jonathan uses large scale population genomic datasets to identify and validate drug targets, and inform precision medicine strategies.